Clinical Trials Browser

Recruiting × INDUSTRY × Pluvicto × Clear all

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Phase 1/2 Recruiting

123 enrolled

Genitourinary

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Phase 2 Recruiting

20 enrolled

Renal Insufficiency

NCT06514521 2025-12-30

Post Marketing Study on Pluvicto in Korea

Recruiting

278 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05803941 2025-04-24

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Phase 4 Recruiting

700 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

P300

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Post Marketing Study on Pluvicto in Korea

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer